Literature DB >> 33091796

Adaptive SBRT by 1.5 T MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time.

Ruggero Ruggieri1, Michele Rigo2, Stefania Naccarato2, Davide Gurrera2, Vanessa Figlia2, Rosario Mazzola2, Francesco Ricchetti2, Luca Nicosia2, Niccolò Giaj-Levra2, Francesco Cuccia2, Claudio Vitale2, Nadejda Stavreva3, Dobromir S Pressyanov3, Pavel Stavrev3, Roberto Pellegrini4, Filippo Alongi5.   

Abstract

PURPOSE: Adaptive Stereotactic Body Radiotherapy (SBRT) of prostate cancer (PC) by online 1.5 T MRi-guidance prolongs session-time, due to contouring and planning tasks, thus increasing the risk of prostate motion. Hence, the interest to verify the adequacy of the delivered dose.
MATERIAL AND METHODS: For twenty PC patients treated by 35 Gy (Dp) in five fractions, daily pre- and post- delivery MRi scans were respectively used for adapt-to-shape (ATS) optimization, and re-computation of the delivered irradiation (Drec). Two expansion recipes, from Clinical (CTV) to Planning target volume (PTV), which slightly differed in the posterior margin were used for groups I and II, of ten patients each. Plans had to assure D95% ≥ 95%Dp to PTV, and D1cc ≤ Dp to rectum, bladder, penile bulb, and urethral planning-risk-volume (urethral-PRV). The adequacy of the delivered dose was estimated by inter-fraction average (ifa) of dose-volume metrics computed from Drec. A cumulative dose (Dsum) was calculated from the five daily Drec deformed onto the simulation MRi.
RESULTS: For each patient, CTV coverage resulted in D95% > 95%Dp when estimated as ifa by Drec. No significant difference for D95% and D99% metrics to CTV resulted between groups I and II. D1cc was < Dp for rectum, urethral-PRV, and penile bulb, whereas < 103.5%Dp for the bladder. Significant correlations resulted between metrics computed by Dsum and as ifa by Drec, by both linear-correlation analysis, and Receiver-Operating-Characteristic curve analysis.
CONCLUSIONS: Our results for PC-SBRT confirm the adequacy of the delivered dose by ATS with 1.5 T MR-linac, and the consistency between dose-volume metrics computed by Drec and Dsum.
Copyright © 2020 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1.5T MR-linac; Cumulative dose; Delivered dose; MRi-guided adaptive radiotherapy; Prostate SBRT

Mesh:

Year:  2020        PMID: 33091796     DOI: 10.1016/j.ejmp.2020.09.026

Source DB:  PubMed          Journal:  Phys Med        ISSN: 1120-1797            Impact factor:   2.685


  8 in total

1.  Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases.

Authors:  Francesco Cuccia; Michele Rigo; Davide Gurrera; Luca Nicosia; Rosario Mazzola; Vanessa Figlia; Niccolò Giaj-Levra; Francesco Ricchetti; Giorgio Attinà; Edoardo Pastorello; Antonio De Simone; Stefania Naccarato; Gianluisa Sicignano; Ruggero Ruggieri; Filippo Alongi
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-15       Impact factor: 4.553

Review 2.  Patient positioning and immobilization procedures for hybrid MR-Linac systems.

Authors:  Francesco Cuccia; Filippo Alongi; Claus Belka; Luca Boldrini; Juliane Hörner-Rieber; Helen McNair; Michele Rigo; Maartje Schoenmakers; Maximilian Niyazi; Judith Slagter; Claudio Votta; Stefanie Corradini
Journal:  Radiat Oncol       Date:  2021-09-20       Impact factor: 3.481

3.  Automated Planning for Prostate Stereotactic Body Radiation Therapy on the 1.5 T MR-Linac.

Authors:  Stefania Naccarato; Michele Rigo; Roberto Pellegrini; Peter Voet; Hafid Akhiat; Davide Gurrera; Antonio De Simone; Gianluisa Sicignano; Rosario Mazzola; Vanessa Figlia; Francesco Ricchetti; Luca Nicosia; Niccolò Giaj-Levra; Francesco Cuccia; Nadejda Stavreva; Dobromir S Pressyanov; Pavel Stavrev; Filippo Alongi; Ruggero Ruggieri
Journal:  Adv Radiat Oncol       Date:  2022-02-12

4.  Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer.

Authors:  Darren M C Poon; Bin Yang; Hui Geng; Oi Lei Wong; Sin Ting Chiu; Kin Yin Cheung; Siu Ki Yu; George Chiu; Jing Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-24       Impact factor: 4.553

5.  1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes.

Authors:  Francesco Cuccia; Michele Rigo; Vanessa Figlia; Niccolò Giaj-Levra; Rosario Mazzola; Luca Nicosia; Francesco Ricchetti; Giovanna Trapani; Antonio De Simone; Davide Gurrera; Stefania Naccarato; Gianluisa Sicignano; Ruggero Ruggieri; Filippo Alongi
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

6.  MRI-guided adaptive radiotherapy for prostate cancer: When do we need to account for intra-fraction motion?

Authors:  R Lawes; H Barnes; T Herbert; A Mitchell; S Nill; U Oelfke; A Pathmanathan; G Adair Smith; K Sritharan; A Tree; H A McNair; A Dunlop
Journal:  Clin Transl Radiat Oncol       Date:  2022-09-08

7.  Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5 T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer.

Authors:  Rosario Mazzola; Gianluisa Sicignano; Francesco Cuccia; Claudio Vitale; Michele Rigo; Niccolò Giaj-Levra; Luca Nicosia; Vanessa Figlia; Francesco Ricchetti; Giorgio Attinà; Edoardo Pastorello; Antonio De Simone; Davide Gurrera; Stefania Naccarato; Ruggero Ruggieri; Filippo Alongi
Journal:  Br J Radiol       Date:  2021-07-20       Impact factor: 3.629

Review 8.  [Primary treatment of prostate cancer using 1.5 T MR-linear accelerator].

Authors:  Daniel Wegener; Daniel Zips; Cihan Gani; Simon Boeke; Konstantin Nikolaou; Ahmed E Othman; Haidara Almansour; Frank Paulsen; Arndt-Christian Müller
Journal:  Radiologe       Date:  2021-07-23       Impact factor: 0.635

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.